CLOMIPHEN al shahba

Description:

CLOMIPHEN ( Clomiphene citrate ) tablets is an orally administered, nonsteroidal, ovulatory stimulant.  Each tablet contains: 50 mg Clomiphene citrate.

Indications:

CLOMIPHEN is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to pregnancy must be excluded or adequately treated before beginning CLOMIPHEN therapy. Those patients most likely to achieve success with Clomiphen therapy include patients with polycystic ovary syndrome, amenorrheagalatorrhea syndrome, psychogenic amenorrhea, post-oral contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.

CLOMIPHEN is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below :

1.Patients who are not pregnant .

2.Patients without ovarian cysts .CLOMIPHEN should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome .

3.Patients without abnormal vaginal bleeding .

4.Patients with normal liver function .

Dosage :

Treatment of the selected patients should begin with a low dose, 50 mg daily ( 1 tablet ) for 5 days. The dose should be increased only in those patients who do not ovulate in the response to cyclic 50 mg CLOMIPHEN. If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has no recent uterine bleeding. When ovulation occurs at this dosage there is no advantages to increasing the dose in subsequent cycles of treatment. If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg daily ( two 50 mg tablets given as a single daily dose ) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended. The majority of patients who are going to ovulate will do so after the first course of therapy if ovulation does not occur after three courses of therapy, further treatment with CLOMIPHEN is not recommended and the patient should be reevaluated. If three ovulatory responses occur, but pregnancy has not achieved, further treatment is not recommended. If menses does not occur after an ovulatory response, the patient should be reevaluated. Long term cyclic therapy is not recommended beyond a total of about six cycles.

Packaging :
Box of 10+20 tablets.